Scholarlink

Background <p>Early pulmonary disease recognition in men is often hindered by nonspecific clinical features and overlapping laboratory parameters. Squamous Cell Carcinoma Antigen (SCCA), a glycoprotein traditionally associated with malignancy, has been proposed as a potential biomarker in a wider spectrum of pulmonary disorders. This study evaluated the diagnostic performance of serum SCCA in pulmonary diseases among the male cohort and determined its relationship with inflammatory markers.</p> Methods <p>We analyzed serum SCCA levels in 533 male patients diagnosed with squamous cell carcinoma (SCC), pneumonia, pulmonary nodules, or chronic obstructive pulmonary disease (COPD) at the Affiliated Hospital of Putian University (January 2017–November 2021), and compared them to 80 healthy male controls. Intergroup differences were assessed, correlations between SCCA and inflammatory markers were analyzed, and receiver operating characteristic (ROC) curves were used to determine disease-specific diagnostic performance.</p> Results <p>Serum SCCA levels differed significantly across disease groups. SCC patients had markedly higher concentrations (7.14 ± 3.64 ng/ml) than all other groups, whereas pulmonary nodules showed the lowest levels (1.45 ± 0.81 ng/ml). SCCA achieved its highest diagnostic accuracy in SCC (AUC = 0.792), outperforming its ability to differentiate other pulmonary conditions.</p> Conclusion <p>Serum SCCA expression shows a promising and supportive biomarker in the diagnostic evaluation of pulmonary diseases among the male patients, meriting further validation in larger, multi-centre studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of squamous cell carcinoma antigen as a diagnostic biomarker in pulmonary diseases: a male cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月29日

查看全文
  • Lin Lirong,
  • Wang Kangying

摘要

Background

Early pulmonary disease recognition in men is often hindered by nonspecific clinical features and overlapping laboratory parameters. Squamous Cell Carcinoma Antigen (SCCA), a glycoprotein traditionally associated with malignancy, has been proposed as a potential biomarker in a wider spectrum of pulmonary disorders. This study evaluated the diagnostic performance of serum SCCA in pulmonary diseases among the male cohort and determined its relationship with inflammatory markers.

Methods

We analyzed serum SCCA levels in 533 male patients diagnosed with squamous cell carcinoma (SCC), pneumonia, pulmonary nodules, or chronic obstructive pulmonary disease (COPD) at the Affiliated Hospital of Putian University (January 2017–November 2021), and compared them to 80 healthy male controls. Intergroup differences were assessed, correlations between SCCA and inflammatory markers were analyzed, and receiver operating characteristic (ROC) curves were used to determine disease-specific diagnostic performance.

Results

Serum SCCA levels differed significantly across disease groups. SCC patients had markedly higher concentrations (7.14 ± 3.64 ng/ml) than all other groups, whereas pulmonary nodules showed the lowest levels (1.45 ± 0.81 ng/ml). SCCA achieved its highest diagnostic accuracy in SCC (AUC = 0.792), outperforming its ability to differentiate other pulmonary conditions.

Conclusion

Serum SCCA expression shows a promising and supportive biomarker in the diagnostic evaluation of pulmonary diseases among the male patients, meriting further validation in larger, multi-centre studies.